FDF / DRUG PRODUCTS in Europe

Sterile liquids and suppositories manufacturing. We handle more than 100 molecules and provide stability studies, narcotics handling and analytical testing...

France Europe

FDF / DRUG PRODUCTS in Europe

Sterile liquids and suppositories manufacturing. We handle more than 100 molecules and provide stability studies, narcotics handling and analytical testing...

FDF / DRUG PRODUCTS  in Europe

About the plant

With over 100 years of experience, our facility focuses on sterile liquids and suppositories manufacturing. We handle more than 100 molecules and provide stability studies, narcotics handling and analytical testing services.

 

Ampoules – Imprinted or Labelled

4 production lines: 2 aseptic with RABS technology and 2 non-aseptic

Aseptic filling or terminal sterilization process by heat

30 to 1,500 liters / 120 million units

Packaging of 1,3,4,5,6,10,20,25 or 50 ampoules

 

3 fully automatic visual inspection lines (optical-cosmetic-pinhole detection-labelling), 2 semi-automatic inspection lines & manual inspection workshop

 

Suppositories

2 filling machines and packaging line PVC-PE and PVC/PVDC/PE.

1 filling machine and packaging line PVC-PE ALU-ALU.

1 Batch from 500 to 2,000 kg / 1 automated workshop

2 Batches from 100 to 600 kg / 1 standard workshop 

90 million units

Suppositories or ovules from 0,9 g to 4,6 g

2 blisters packaging lines

Platelets to 4,5,6 suppositories

Boxes to 5,8,10,12,30 suppositories


Certifications
  • EMA (EU GMP)
  • MFDS/KFDA (Republic of Korea GMP)

Activity
  • Topical, mucosal and transdermal, Injectables, Suppositories and vaginal ovules, tablets, capsules, rings, Terminal sterilization, Fill&Finish, Glass ampoules, FDF / DRUG PRODUCTS manufacturing

Features
  • Uses: Investigational, Commercial (Phase IV), Preclinical, Phase I, Phase II, Phase III, Human, Veterinary
  • Toxicity (OEB classification): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 5 / HPAPI (PDE < 10 µg/day)
  • DEA: Schedule I (high potential for abuse / no medical use), Schedule II (high potential for abuse / medical use), Schedule III (lower potential for abuse), Schedule IV (low potential for abuse), Schedule V (lowest potential for abuse)
  • BSL:
  • Therapeutic areas: N/A
  • Markets: FDA (USA), EMA (EU), PMDA (Japan), CDSCO (India), Health Canada (Canada), MHRA (UK), TGA (Australia), NMPA (China), EDE (UAE), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), SFDA (Saudi Arabia)

Batch Size / Reactor
  • Small, Medium, Large

Services
  • Regulatory services, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging, Logistics, Stability studies design, Stability studies execution, ICH Stability studies, Tech transfer, Formulation mixing, Research batches, Engineering batches, Pilot batches, Registration batches, Batch records, Analytical methods development, Analytical methods validation, Release testing of raw materials, Release testing of product, Analytical methods transfer, Batch certification / release, GMP documentation, Primary packaging, Secondary packaging, Labeling, Storage

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

FAES FARMA
Shilpa Biologicals
Salvat
Grifols
Histocell
VIVUNT